HeimTMOF • VIE
add
Thermo Fisher Scientific Inc
Við síðustu lokun
494,60 €
Dagbil
483,55 € - 492,30 €
Árabil
338,30 € - 585,40 €
Markaðsvirði
213,27 ma. USD
Meðalmagn
18,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 11,12 ma. | 4,94% |
Rekstrarkostnaður | 2,45 ma. | 0,99% |
Nettótekjur | 1,62 ma. | -0,86% |
Hagnaðarhlutfall | 14,53 | -5,53% |
Hagnaður á hvern hlut | 5,79 | 9,66% |
EBITDA | 2,82 ma. | 5,75% |
Virkt skatthlutfall | 11,32% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,55 ma. | -46,64% |
Heildareignir | 103,02 ma. | 2,65% |
Heildarskuldir | 51,87 ma. | 1,17% |
Eigið fé alls | 51,15 ma. | — |
Útistandandi hlutabréf | 375,71 m. | — |
Eiginfjárgengi | 3,64 | — |
Arðsemi eigna | 5,25% | — |
Ávöxtun eigin fjár | 6,21% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,62 ma. | -0,86% |
Handbært fé frá rekstri | 2,24 ma. | 3,37% |
Reiðufé frá fjárfestingum | -4,12 ma. | -15,23% |
Reiðufé frá fjármögnun | -632,00 m. | 46,89% |
Breyting á handbæru fé | -2,59 ma. | -6,80% |
Frjálst peningaflæði | 1,47 ma. | -21,49% |
Um
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Framkvæmdastjóri
Stofnsett
1956
Höfuðstöðvar
Vefsvæði
Starfsfólk
125.000
